We're #hiring a new VP, Finance and Corporate Controller in South San Francisco, California. Apply today or share this post with your network.
Trace Neuroscience
Biotechnology Research
South San Francisco, California 3,467 followers
Breakthrough Science for People Suffering from Neurodegenerative Diseases
About us
Launched in 2024, Trace Neuroscience is a biopharmaceutical company on a mission to expand the promise of genomic medicine for people living with neurodegenerative diseases. With an initial focus on ALS, the company is developing novel therapies to restore UNC13A protein function to re-establish healthy communication between nerves and muscle cells.
- Website
-
www.traceneuro.com
External link for Trace Neuroscience
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- South San Francisco, California
- Type
- Privately Held
- Founded
- 2024
Locations
-
Primary
Get directions
750 Gateway Blvd
Suite 200
South San Francisco, California 94080, US
Employees at Trace Neuroscience
Updates
-
The Trace team loved spending time with David Buseck and Linda Levine, learning how they approach life with #ALS with such positivity and purpose. Their adventurous spirit and resilience left us truly inspired! To learn more about David and Linda, visit their websites: www.SurpriseEnterprise.com www.DavidBuseck.com Donate to the ALS Network through Team Tortoise: https://lnkd.in/exW8jjqi
-
-
1 in 400 people around the world will be diagnosed with ALS during their lifetime. A year ago today, we made our public debut as Trace Neuroscience in hopes to expand the promise of genetic medicine to all people with #ALS. Each day since, we've been working alongside the incredible ALS community and our dedicated team to bring that vision closer to reality. We're excited for all that's to come in this journey during year two.
-
-
We're thrilled that Nature has published Scientific Advisory Board member Noa Lipstein's latest study on pathogenic UNC13A variants and their link to neurodegenerative diseases like #ALS. Co-authored by Trace team members Shila Mekhoubad, Ryan Morrie and Eric Green, these findings underscore how important UNC13A is to the nervous system, and suggest that restoring its expression could benefit people living with ALS. Read more from CEO Eric Green.
At Trace Neuroscience , our mission begins at the synapse. Every movement, thought, and memory depends on the precise communication between neurons. When that communication fails, neurologic disease emerges. A new study led by Noa Lipstein, a member of the Trace Scientific Advisory Board, and co-authored by Trace scientists, highlights just how fundamental this process is. The paper characterizes a neurodevelopmental syndrome caused by mutations in UNC13A, a presynaptic protein required for neurotransmitter release. These findings add to the existing body of human genetics evidence linking UNC13A with ALS and frontotemporal dementia. https://lnkd.in/gCSVEFrf The authors describe three distinct mechanisms by which UNC13A dysfunction can disrupt neural communication: --Loss of UNC13A protein to ~20–30 % of normal, weakening synaptic strength --Gain-of-function variants that make synapses overactive --Misregulated signaling that disrupts short-term synaptic plasticity Based on these findings, they proposed that even half of the normal levels of UNC13A can support neuronal function — a critical insight for therapeutic development. Our lead program at Trace is an antisense oligonucleotide designed to correct UNC13A splicing errors in ALS, restoring protein expression and preserving the synaptic communication that keeps neurons alive. These new data validate the importance of UNC13A in the nervous system and the potential benefit of restoring its expression in people with ALS. Congratulations to Noa and all the authors on this important contribution.
-
Meet Trace scientist, Ryan Morrie. His personal commitment to getting people with #ALS and their families new options they desperately need and passion for neuroscience make him a stand-out member of our incredible team. He shares more about himself below.
-
As Fierce Biotech put it, this year's #Fierce15 share one main common thread: "they're all challenging old ways of working." We were privileged to celebrate with our fellow 2025 honorees last night. Patients living with chronic, life-changing diseases like #ALS deserve the best science, innovation, leadership, and collaboration we can offer them. We're proud to be recognized as one of the organizations redefining biotech.
-
-
We are headed to the NEALS Consortium annual meeting this week and look forward to connecting with our #ALSResearch community. Make sure to stop by our lightning talk & posters featuring team members CMO Irina Antonijevic, COO Megan Baierlein and Head of Translational Sciences Sanjay Chandriani. Details below. See you there! #NEALS2025
-
We had an incredible Saturday attending the ALS Network Ride, Walk & Roll to #CureALS alongside so many inspiring families, caretakers and individuals impacted by #ALS. We're honored to play a small part in advancing research and treatments for this life-altering disease.
-
-
At Trace, we are proud to support the Muscular Dystrophy Association and their leadership in funding for ongoing research in many neuromuscular diseases. We join them in their commitment to building a future for patients and their families where a longer, more fulfilling life is possible. #MDAStrong
🔬 The Muscular Dystrophy Association has led the charge in funding groundbreaking research on over 40 different neuromuscular diseases. With $36 million currently being invested, MDA is supporting 100+ scientists, pioneering advances like gene therapy, gene editing, and the discovery of disease-causing genes. MDA is not only shaping today’s treatments, but we’re also building a stronger future.💪 Through our Development Grants, we’ve helped train over 2,000 emerging scientists, ensuring the next generation of researchers and clinicians is ready to carry the torch.🌟 We are committed to a future where everyone living with neuromuscular diseases can live longer, fuller lives. 👉 Learn more about our research program at https://lnkd.in/d428wGNA #MDAresearch #MDAstrong #MDA75 #Neuromuscular #MuscularDystrophyAwarenessMonth
-
-
We are humbled and delighted to be named as one of the best in biotech on this year's #Fierce15. This recognition highlights our dedication to changing therapy options for those living with #ALS, which are limited in efficacy for many patients. We're rooted in cutting-edge science, inspired by people living with ALS. This year's list from Fierce Biotech - https://lnkd.in/gCJNmr87
-